Three major benefits suddenly arrive! This sector has completely exploded!

On April 1st, Jin10 Data reported that this morning, innovative drugs suddenly became the market's main force, with the innovative drug index soaring nearly 6%. Stocks such as Chengda Pharmaceutical, Aidea Pharma, ApicHope, RemeGen, Jiankai Technology, and HitGen saw their prices hit the daily limit or rise over 10%. Why did this long-silent sector suddenly explode? Analysts believe that, on one hand, this sector was not previously a hotspot and was not crowded, making it suitable as a defensive variety, thus becoming a target for capital investment; on the other hand, it is also related to some unexpected positive news. First, the State-owned Assets Supervision and Administration Commission encourages state-owned enterprises to carry out mergers and acquisitions in the biopharmaceutical field. Second, there are strong expectations for the optimization of centralized procurement, as the National Healthcare Security Administration held a meeting on March 26th to optimize the pharmaceutical procurement work, and the market expects the meeting to advance the optimization details of drug procurement. At the same time, the market is also discussing a document titled "Plan for Further Optimizing Drug Procurement Policies (Draft for Comments)." Third, the General Administration of Market Supervision recently publicly solicited opinions on "Measures to Optimize Lifecycle Supervision to Support the Innovative Development of High-end Medical Devices (Draft for Comments)."